SNAP-8, also sold as Acetyl Octapeptide-3, is a cosmetic octapeptide that reduces facial muscle contractions for an anti-wrinkle, Botox-adjacent effect. There is no FDA-approved indication, so every human use is off-label or compounded, and the underlying research is preclinical and animal-only rather than trial-backed. Reported doses run from 2 mg to 30 mg, most commonly around 10 mg, though most people posting about it don't state a schedule. Given how thin the evidence base is, treat the wrinkle claims as unproven in humans rather than settled.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The evidence for SNAP-8 is animal-only, with no human published studies. There is one mapped indication, which is supported by preclinical or mechanistic research in animals. No completed trials have been conducted, indicating a lack of robust clinical evidence to support its use for any indication.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How SNAP-8 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Across 8 community reports, doses cluster around 10 mg subQ, with a wide spread from 2 mg to 30 mg. Most sources don't specify frequency; of the two that do, one reports 2–2.5 mg daily and another 4 mg weekly.